Boston Technology Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Boston Technology Review.

Press releases published on October 5, 2026

Oct. 5, 2026

Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa ODM-216-molekyylillä, joka on yhtiön ensimmäinen kliiniseen kehitysvaiheeseen edennyt biologinen syöpälääkeaihio

Indeterminate GlobeNewswire

Oct. 5, 2026

PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

Indeterminate GlobeNewswire

Oct. 5, 2026

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

Indeterminate GlobeNewswire

Oct. 5, 2026

4DMT to Host Investor Day on October 21, 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Indeterminate GlobeNewswire

Oct. 5, 2026

Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer

Indeterminate GlobeNewswire

Oct. 5, 2026

OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting

Indeterminate GlobeNewswire

Oct. 5, 2026

Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development

Indeterminate GlobeNewswire

Oct. 5, 2026

Magnite to Announce Third Quarter 2026 Financial Results on November 4, 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

Indeterminate GlobeNewswire

Oct. 5, 2026

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Indeterminate GlobeNewswire

Oct. 5, 2026

Sofwave to Participate in the Jefferies Private MedTech Virtual Summit

Indeterminate GlobeNewswire

Oct. 5, 2026

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Indeterminate GlobeNewswire

Oct. 5, 2026

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

Indeterminate GlobeNewswire

Oct. 5, 2026

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

Indeterminate GlobeNewswire

Oct. 5, 2026

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Indeterminate GlobeNewswire

Oct. 5, 2026

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Indeterminate GlobeNewswire

Oct. 5, 2026

Zscaler Collaborates with IBM and Red Hat to Protect Private Applications from Frontier AI-Powered Threats

Indeterminate GlobeNewswire

Oct. 5, 2026

Coveron completes SOC 2 Type II certification with zero exceptions

Indeterminate GlobeNewswire